Hyperfine Inc (HYPR)vsStryker Corporation (SYK)
HYPR
Hyperfine Inc
$0.72
+4.98%
HEALTHCARE · Cap: $73.43M
SYK
Stryker Corporation
$335.08
-2.75%
HEALTHCARE · Cap: $111.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 158937% more annual revenue ($26.30B vs $16.54M). SYK leads profitability with a 13.8% profit margin vs -210.7%. SYK earns a higher WallStSmart Score of 57/100 (C).
HYPR
Avoid30
out of 100
Grade: F
SYK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HYPR.
Margin of Safety
-23.8%
Fair Value
$235.79
Current Price
$335.08
$99.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 44.8% year-over-year
Reasonable price relative to book value
Large-cap with strong market position
Strong operational efficiency at 20.3%
Generating 1.1B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -101.2% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 11.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : HYPR
The strongest argument for HYPR centers on Revenue Growth, Price/Book. Revenue growth of 44.8% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap, Operating Margin, Free Cash Flow. PEG of 1.37 suggests the stock is reasonably priced for its growth.
Bear Case : HYPR
The primary concerns for HYPR are EPS Growth, Market Cap, Return on Equity.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
HYPR profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.
HYPR carries more volatility with a beta of 1.50 — expect wider price swings.
HYPR is growing revenue faster at 44.8% — sustainability is the question.
SYK generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (57/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hyperfine Inc
HEALTHCARE · MEDICAL DEVICES · USA
Hyperfine Inc. is a pioneering force in medical technology, renowned for developing the world’s first FDA-cleared portable MRI system, which significantly enhances diagnostic imaging accessibility at the point of care. By combining innovation with cost-efficiency, the company improves patient outcomes and facilitates rapid clinical decision-making. As healthcare continues to evolve, Hyperfine is strategically positioned to capture growth opportunities within the expanding imaging diagnostics market, presenting a compelling investment prospect for institutional investors focused on transformative healthcare solutions.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?